Patent · US Active

Antibodies against factor XI and uses thereof

US10654941B2 · kind B2 · utility

0Cited by

7References

20Claims

0Family size

Assignees

Bayer Pharma Aktiengesellschaft · DE
Aronora, Inc. · US

Inventors

Andreas Wilmen · Neunburg vorm Wald, DE
Anja Buchmüller · Essen, DE
Erik I. Tucker · Portland, US

Key dates

Filing date	Sep 18, 2017
Grant date	May 19, 2020
Priority date	—
Expiry date	Sep 18, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.